JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Gino Gerosa
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by di Marco, F.
Right arrow Articles by Gerosa, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by di Marco, F.
Right arrow Articles by Gerosa, G.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Valve disease

J Thorac Cardiovasc Surg 2005;130:1482-1483
© 2005 The American Association for Thoracic Surgery

Letter to the Editor

Early anticoagulation after aortic valve replacement with bioprostheses: Time to abandon it?

Francesca di Marco, MD a , Giorgio Meneghetti, MD b , Gino Gerosa, MD a

a Institute of Cardiovascular Surgery, Padua University Medical School, Padova, Italy
b Neurology Division, Padua University Medical School, Padova, Italy

The first 20% of the full text of this article appears below.

To the Editor:

According to the American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for Valvular Heart Disease, 1 Go a 3-month-long program of anticoagulation therapy is recommended after valve replacement with tissue valves. On the contrary, a recent study carried out by the Cardiothoracic Surgery Network (CTSNet) Valve Technology Center, "The Anticoagulation Therapy and Valve Replacement Study," 2 Go has outlined that the practice tends to diverge from the widely established guidelines. In fact, 80% of 726 participating surgeons prefer to adopt antiplatelet therapy in biologic valve recipients who . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
F. di Marco, S. Grendene, G. Feltrin, D. Meneghetti, and G. Gerosa
Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety
J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1597 - 1603.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
F. di Marco, M. Giordan, and G. Gerosa
Early antithrombotic therapy after aortic valve replacement with tissue valves: When the practice diverges from the guidelines
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1223 - 1223.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
P. Vaughan and P. D. Waterworth
Anticoagulation after bioprosthetic aortic valve replacement
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1425 - 1425.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.